refractory/relapsed Positive CD19+ B-cell malignant lymphoma
Conditions
Interventions
Low dose level:infuse 1.0×10^6 CAR+ T Cells/kg
High dose level:infuse 1.0×10^7 CAR+ T Cells/kg
Sponsors
Hebei Yanda Lu Daopei Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Histopathological diagnosis as CD19-positive B-cell non-Hodgkin's lymphoma; 2. Age between 3-80 years old; 3. Meet one of the following three situations, all can be included (1) Patients who have received a standard chemotherapy regimen and a rescue regimen for patients with relapsed or refractory B-cell lymphoma. The chemotherapy regimen is rituximab or other CD20 antibody drugs and at least two types of chemotherapy suitable for their disease Protocol, one of the chemotherapy should include anthracycline antibiotics; after these regimens, the patient maintains SD (SD duration = 50%, cardiac ultrasound showed no pericardial effusion. 6. US Eastern Cooperative Oncology Group (ECOG) Scale of Performance <= 3 points; 7. The patient can understand and voluntarily sign the informed consent form; if the subject is a child, the guardian signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Pregnant or nursing woman 2. Uncontrolled infection 3. Active hepatitis B or hepatitis C 4. Patients who used steroids within a week before cell infusion 5. Patients who used merova within two weeks before cell infusion 6. Drug-uncontrollable central nervous system lesions 7. HIV infected patients 8. Other diseases that conflict with this study, including cardiovascular, neurological, psychiatric disorders, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PBMC CAR-T+Tcell, CD19+Bcell;remission rate of lymphoma; | — |
Countries
China
Contacts
Public ContactXian Zhang
Hebei Yanda Lu Daopei Hospital
Outcome results
None listed